About

About the Taylor Family Institute’s Mission

The Taylor Family Institute for Psychiatric Research is focused on the need to develop novel treatments. Psychiatric illnesses permeate our world and affect those around us in myriad seen — and unseen — ways. According to estimates from the World Health Organization, psychiatric disorders affect more than 80 million Americans and roughly 25 percent of people throughout the world. Psychiatric disorders represent a common thread underlying many other disabilities and causes of death, including suicide. They also are a driving factor behind hospital readmission rates.

Looking Beyond A One-Size-Fits-All Treatment Model

Psychiatric illnesses are a heterogenous collection of disorders characterized by dysfunction of brain networks, ultimately leading to symptoms involving emotion, motivation and cognition. There is no one set path to a good outcome for those affected with psychiatric illness. Yet pharmacological treatments for psychiatric disorders have remained relatively unchanged over the last 25 years. Serotonin reuptake inhibitors (SSRIs), the last class of psychiatric drugs developed for treating depression, target the same systems as psychiatric drugs that were available thirty years earlier. Many current medications used to treat psychiatric disorders, although offering help to those affected, have major limitations in terms of effectiveness and potential side effects. The development of novel pharmacological treatments offers some of the greatest hope for diminishing the impact of psychiatric illnesses.

There is no one set path to a good outcome for those affected with psychiatric illness. Yet pharmacological treatments for psychiatric disorders have remained relatively unchanged over the last 25 years. Serotonin reuptake inhibitors (SSRIs), the last class of psychiatric drugs developed for treating depression, target the same systems as psychiatric drugs that were available thirty years earlier.

Many current medications used to treat psychiatric disorders, although offering help to those affected, have major limitations in terms of effectiveness and potential side effects. The development of novel pharmacological treatments offers some of the greatest hope for diminishing the impact of psychiatric illnesses.

About The Taylor Family Institute for Innovative Psychiatric Research

In an environment of increasingly limited funding from the National Institutes of Health (NIH), the Taylor Family Institute for Innovative Psychiatric Research seeks to advance the development of treatment options for those affected with psychiatric disorders by providing support for both laboratory and clinical collaborations.

The Institute was launched in 2012 with the visionary support of the Andrew and Barbara Taylor and the Crawford Taylor Foundation. Members of the Institute will drive laboratory and clinical research at Washington University focused on new treatment development in psychiatry and will involve collaborations among several departments, including psychiatry, anesthesiology, developmental biology, radiology and neurology.

The core strengths of Institute scientists encompass biochemical, biophysical, physiological and behavioral research, and drug discovery.

Understanding the genetics, neurocircuitry and biology of psychiatric and neurological disorders is important for developing much needed treatments for the many individuals, families and friends living with the effects of these devastating illnesses. Learn more about the work of core members.

Your support to help cure and prevent psychiatric illness is vital. Join with us in our mission to help change the future.
Ways to Give